Journal of the American Academy of Dermatology
-
J. Am. Acad. Dermatol. · May 2013
Randomized Controlled TrialA double-blind, randomized, placebo-controlled trial of adalimumab in the treatment of cutaneous sarcoidosis.
Many medications, including tumor necrosis factor antagonists, have been anecdotally reported to be effective in treating cutaneous sarcoidosis, but controlled study is lacking. ⋯ Adalimumab, at the dose and duration of treatment used in this study, is likely to be an effective and relatively safe suppressive treatment for cutaneous sarcoidosis.